Optimum population-level use of artemisinin combination therapies: a modelling study.

Optimum population-level use of artemisinin combination therapies: a modelling study.

Artemisinin combination therapies (ACTs) are used worldwide as first-line treatment against confirmed or suspected Plasmodium falciparum malaria. Despite the success of ACTs at reducing the global burden of malaria, emerging resistance to artemisinin threatens these gains. Countering onset of resist...

Full description

Bibliographic Details
Main Authors:	Nguyen, T, Olliaro, P, Dondorp, A, Baird, J, Lam, H, Farrar, J, Thwaites, G, White, N, Boni, M
Format:	Journal article
Language:	English
Published:	Elsevier 2015

Similar Items

Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
by: Nguyen, TD, et al.
Published: (2023)

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?
by: van der Pluijm, RW, et al.
Published: (2022)

Artemisinin combination therapy for vivax malaria.
by: Douglas, N, et al.
Published: (2010)

Artemisinin-based combinations.
by: Ashley, E, et al.
Published: (2005)

Triple artemisinin-based combination therapies for malaria – a new paradigm?
by: van der Pluijm, RW, et al.
Published: (2020)

Access to artemisinin combination therapy for malaria in remote areas of Cambodia.
by: Yeung, S, et al.
Published: (2008)

Cost of increasing access to artemisinin combination therapy: the Cambodian experience.
by: Yeung, S, et al.
Published: (2008)

PHARMACOKINETICS OF ARTEMISININ COMBINATION THERAPY IN CHILDREN IN KAMPALA, UGANDA
by: Mwesigwa, J, et al.
Published: (2008)

Artemisinin combination therapy for malaria: beyond good efficacy.
by: Price, R, et al.
Published: (2009)

Population pharmacokinetic and pharmacodynamic modeling of artemisinin resistance in Southeast Asia
by: Lohy Das, J, et al.
Published: (2017)

Artemisinin and derivatives in the treatment of uncomplicated malaria.
by: White, N, et al.
Published: (1998)

Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices.
by: Yeung, S, et al.
Published: (2004)

Modulation of triple artemisinin-based combination therapy pharmacodynamics by Plasmodium falciparum genotype
by: Ansbro, MR, et al.
Published: (2020)

Potential of artemisinin-based combination therapies to block malaria transmission.
by: Price, R
Published: (2013)

HERITABILITY OF PARASITE CLEARANCE TIME FOLLOWING ARTEMISININ COMBINATION THERAPY
by: Anderson, T, et al.
Published: (2008)

Artemisinin-based combination treatment of falciparum malaria.
by: Nosten, F, et al.
Published: (2007)

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
by: Miotto, O, et al.
Published: (2020)

Modelling antimalarial drug resistance amd the cost-effectiveness of different coverage rates with Artemisinin Combination Therapies (ACTs)
by: Yeung, S, et al.
Published: (2007)

Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations
by: Tindana, P, et al.
Published: (2021)

Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.
by: Lawford, H, et al.
Published: (2011)

Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis
by: Dahal, P, et al.
Published: (2022)

Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model
by: Scott, N, et al.
Published: (2018)

Neuropathologic toxicity of artemisinin derivatives in a mouse model.
by: Nontprasert, A, et al.
Published: (2002)

Artemisinin resistance in falciparum malaria
by: Dondorp, A
Published: (2012)

Artemisinin Resistance in Plasmodium falciparum Malaria REPLY
by: Dondorp, A, et al.
Published: (2009)

Intrahost modeling of artemisinin resistance in Plasmodium falciparum
by: Saralamba, S, et al.
Published: (2010)

Intrahost modeling of artemisinin resistance in Plasmodium falciparum.
by: Saralamba, S, et al.
Published: (2011)

Artemisinin resistance--modelling the potential human and economic costs
by: Lubell, Y, et al.
Published: (2014)

The community as the patient in malaria-endemic areas: Preempting drug resistance with multiple first-line therapies.
by: Boni, M, et al.
Published: (2016)

Investigating the efficacy of triple artemisinin-based combination therapies (TACTs) for treating Plasmodium falciparum malaria patients using mathematical modelling
by: Dini, S, et al.
Published: (2018)

RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE
by: Maude, R, et al.
Published: (2010)

Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis
by: Okell, L, et al.
Published: (2014)

Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Medecins Sans Frontieres.
by: Guthmann, J, et al.
Published: (2008)

Artemisinin: current status.
by: White, N
Published: (1994)

Defining the optimal management of Plasmodium falciparum malaria on a background of emerging artemisinin combination therapy resistance
by: Phyo, A
Published: (2017)

Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance
by: Mok, S., et al.
Published: (2016)

Artemisinin resistance is a clear and present danger
by: Dondorp, A, et al.
Published: (2013)

Artemisinin resistance is a clear and present danger.
by: Dondorp, A, et al.
Published: (2013)

Artemisinin resistance: current status and scenarios for containment.
by: Dondorp, A, et al.
Published: (2010)

Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia.
by: Miotto, O, et al.
Published: (2013)